Patents by Inventor Christian Bacilieri

Christian Bacilieri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST
    Publication number: 20240368085
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Application
    Filed: July 14, 2024
    Publication date: November 7, 2024
    Inventors: Christian Bacilieri, Gionata Frasca
  • Crystalline forms of an NK-1 antagonist
    Patent number: 12071406
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: August 27, 2024
    Assignee: Helsinn Healthcare SA
    Inventors: Christian Bacilieri, Gionata Frasca
  • CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST
    Publication number: 20210269401
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Application
    Filed: February 25, 2021
    Publication date: September 2, 2021
    Inventors: Christian Bacilieri, Gionata Frasca
  • Crystalline forms of an NK-1 antagonist
    Patent number: 10961195
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: March 30, 2021
    Assignee: Helsinn Healthcare SA
    Inventors: Christian Bacilieri, Gionata Frasca
  • CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST
    Publication number: 20200255381
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventors: Christian Bacilieri, Gionata Frasca
  • Crystalline forms of an NK-1 antagonist
    Patent number: 10676440
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 9, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Christian Bacilieri, Gionata Frasca
  • CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST
    Publication number: 20190152915
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 23, 2019
    Inventors: Christian Bacilieri, Gionata Frasca
  • Crystalline forms of an NK-1 antagonist
    Patent number: 10233154
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 19, 2019
    Assignee: Helsinn Healthcare SA
    Inventors: Christian Bacilieri, Gionata Frasca
  • Crystalline Forms of an NK-1 Antagonist
    Publication number: 20180201581
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Inventors: Christian Bacilieri, Gionata Frasca
  • Crystalline forms of an NK-1 antagonist
    Patent number: 9951016
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 24, 2018
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Christian Bacilieri, Gionata Frasca
  • Crystalline Forms of an NK-1 Antagonist
    Publication number: 20160090359
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Application
    Filed: September 25, 2015
    Publication date: March 31, 2016
    Applicant: HELSINN HEALTHCARE SA
    Inventors: Christian Bacilieri, Gionata Frasca